Mirum Pharmaceuticals, Inc.
950 Tower Lane, Suite 1050
Foster City, CA 94404
June 6, 2022
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Margaret Schwartz
| RE: | Mirum Pharmaceuticals, Inc. |
Registration Statement on Form S-3
Filed May 25, 2022
File No. 333-265210
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on June 9, 2022, or as soon thereafter as is practicable.
Thank you for your assistance. If you should have any questions, please contact Alexa Ekman of Cooley LLP, counsel to the Registrant, at (858) 550-6183.
| MIRUM PHARMACEUTICALS, INC. | ||
| By: | /s/ Christopher Peetz | |
| Christopher Peetz | ||
| President and Chief Financial Officer | ||
